View printer-friendly version << Back

NOVAVAX to Present at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

ROCKVILLE, Md., Sept 08, 2010 /PRNewswire via COMTEX/ --

Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the American Society for Microbiology (ASM) sponsored, ICAAC. The Conference will take place September 11-15, 2010 at the Boston Convention and Exhibition Center, Boston, MA. Drs. Steven Pincus and Ramadevi Raghunandan will be presenting multiple abstracts including, "Functional Neuraminidase Plays a Key Role in Enhancing Immune Response and Protection against Influenza Virus," and "Immunization of Healthy Adults with H5N1 Influenza Virus-Like Particle (VLP) Vaccine Induces Cell Mediated and Humoral Immunity Including Functional Antibodies against Neuraminidase," during the poster sessions on Sunday, September 12, 2010, and Tuesday, September 14, 2010.

These two Novavax presentations, mentioned above, have been selected by the ASM Communications Committee and the ICAAC Program Committee to be highlighted in the conference's press room.

"We are all excited that ASM is recognizing our work as novel and newsworthy," said Dr. Raghunandan.

About ASM and ICAAC

The ASM is the world's largest scientific society of individuals interested in the microbiological sciences. The mission of the American Society for Microbiology is to advance the microbiological sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health and environmental and economic well-being worldwide. For 50 years, ICAAC has presented science of the highest scientific quality with an international focus and late-breaking information. More than 10,000 physicians, researchers and other healthcare professionals from around the globe will gather at the 50th ICAAC to foster worldwide solutions to the problem of infectious disease. For more information, please see

About Novavax

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website:

SOURCE Novavax, Inc.

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.